ArticleWorld journal of gastrointestinal endoscopy2026
Purastat therapy for bleeding radiation proctopathy.
Article in World journal of gastrointestinal endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cystoscopic RADA16 (PuraStat) for persistent severe haematuria secondary to radiation cystitis: an exploratory prospective two-centre study.World journal of urology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are limited data as to the effectiveness of Purastat to treat bleeding radiation proctopathy. We present prospectively collected data from a consecutive series of 11 patients with severely symptomatic bleeding radiation proctopathy treated with Purastat. Bleeding reduced after treatment and became very minor or occasional or stopped completely, in all patients after a median of 3 treatments. Two thirds of patents improved with each treatment, one third needed two or more treatments before bleeding reduced. Nuisance scores before treatment were a median 8.5/10 and fell to 0.5/10 at last follow up. The improvement seen was sustained over time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.